TABLE 2.
Intra-operative characteristics of LuTX.
| TLVRS (n = 26) | CLVRS (n = 328) | p = | TELVR (n = 56) | CELVR (n = 270) | p = | ||
|---|---|---|---|---|---|---|---|
| Size reduction of the graft | No | 19 (73.1%) | 78.4% | 0.532 | 41 (73.2%) | 74.9% | 0.802 |
| Yes | 7 (26.9%) | 21.6% | 15 (26.8%) | 25.1% | |||
| Which size reduction | Wedge unilat. | 2 (7.7%) | 7.3% | 0.785 | 2 (3.6%) | 7.4% | 0.512 |
| Wedge. bilat. | 5 (19.2%) | 14.2% | 13 (23.2%) | 15.9% | |||
| Lobe unilat. | 0.1% | 0.5% | |||||
| Lobe bilat. | 1.2% | ||||||
| Intra-OP ECS | None | 9 (36.0%) | 33.5% | 0.069 | 12 (21.4%) | 18.1% | 0.747 |
| CPB | 5.7% | 1 (1.8%) | 2.4% | ||||
| vaECMO | 15 (60.0%) | 60.4% | 43 (76.8%) | 77.9% | |||
| vvECMO | 1 (4.0%) | 0.3% | 1.5% | ||||
| LuTX duration (min) | 348 (137–705) | 323 (150–743) | 0.296 | 283 (150–660) | 288 (137–705) | 0.703 | |
| TIT 1st implanted side (min) | 295 (173–577) | 293 (158–812) | 0.816 | 285 (175–542) | 299 (158–698) | 0.051 | |
| TIT 2nd implanted side (min) | 465 (218–639) | 403 (235–960) | 0.101 | 360 (235–692) | 380 (218–769) | 0.180 | |
Data expressed as median (range) or counts (%); control columns consist of weighted data; TLVRS, patients with previous LVRS; CLVRS, matched controls; TELVR, patients with previous ELVR; CELVR, matched controls; ECS, extra corporeal support; CPB, cardio-pulmonary bypass; vaECMO, veno-arterial extracorporeal membrane oxygenation; vvECMO, veno-venous ECMO; TIT, total ischemic time of the graft. Significant p values are highlited in bold italic.